Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-04-15 Sale | 2024-04-16 4:16 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate Dev | 1,990 | $137.81 | $274,242 | 42,377 (Direct) | View |
| 2024-03-15 Sale | 2024-03-19 4:55 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy & Corp Dev | 4,203 | $130.21 | $547,259 | 44,367 (Direct) | View |
| 2024-03-12 Sale | 2024-03-14 5:39 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate | 6,710 | $134.41 | $901,896 | 48,570 (Direct) | View |
| 2023-09-01 Sale | 2023-09-01 6:40 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 56 | $102.32 | $5,730 | 33,569 (Direct) | View |
| 2023-03-16 Sale | 2023-03-17 4:14 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 2,303 | $115 | $264,845 | 33,569 (Direct) | View |
| 2023-03-13 Sale | 2023-03-14 4:46 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 6,229 | $106.27 | $661,956 | 35,872 (Direct) | View |
| 2023-03-06 Sale | 2023-03-06 8:04 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 226 | $114.4 | $25,854 | 26,536 (Direct) | View |
| 2022-09-01 Sale | 2022-09-06 09:33 am | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 5 | $81.63 | $408 | 26,536 (Direct) | View |
| 2022-03-15 Sale | 2022-03-17 4:30 pm | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Development | 2,186 | $424.68 | $928,359 | 6,634 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-08 Option Award | 2024-03-11 6:30 pm | N/A N/A | DEXCOM INC | DXCM | Dolan Matthew Vincent EVP Strategy and Corporate | 21,711 | $0 | 55,280 (Direct) | View |
| 2023-03-10 Disposition | 2023-03-14 4:46 pm | N/A N/A | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 6,204 | $111.4 | 35,872 (Direct) | View |
| 2023-03-08 Option Award | 2023-03-10 4:00 pm | N/A N/A | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Strategy-Develop | 21,769 | $0.001 | 48,305 (Direct) | View |
| 2022-03-09 Disposition | 2022-03-10 7:24 pm | N/A N/A | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Development | 1,615 | $406.06 | 8,820 (Direct) | View |
| 2022-03-08 Option Award | 2022-03-10 7:24 pm | N/A N/A | DEXCOM INC | DXCM | Dolan Matthew Vincent SVP Corporate Development | 2,889 | $0.001 | 8,820 (Direct) | View |
Ownership | 2022-03-10 5:39 pm | N/A N/A | DEXCOM INC | DXCM | Dolan Matthew Vincent * | 0 | $0 | 7,546 (Direct) | View |